- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00891826
Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability
April 11, 2013 updated by: W. Emanuel Severus, Ludwig-Maximilians - University of Munich
Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability: the "BIPO-3" Trial
This study sets out to test the hypothesis that parameters of heart rate variability, as a non-invasive measure of cardiovascular risk, can be improved by the addition of omega-3 fatty acids in euthymic bipolar patients with a low omega-3 index and reduced heart rate variability.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 80336
- Department of Psychiatry, University of Munich
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must meet the DSM-IV criteria for bipolar disorders, in remission
- Age: 18 - 65 years
- Low omega-3 index (<5%)
- SDNN < 60 msec
- Subjects must have adequate fluency in German or English to complete baseline and follow-up interviews and fill out the Beck Depression Inventory
- Stable psychotropic medication for at least 2 weeks
- Subjects must be able to give written informed consent
Exclusion Criteria:
- Subjects for whom the intake of omega-3 fatty acids is indicated according to recent treatment guidelines
- Patients on Warfarin
- Subjects with any acute and life-threatening condition, such as collapse and shock, acute myocardial infarction, stroke, embolism
- Subjects with significant medical comorbidity
- Pregnant subjects - due to any possible teratogenic effects of EPAX 6015 TG and corn oil, respectively, on the fetus - and breastfeeding subjects. In addition, women of childbearing potential who will not practice a medically accepted method of contraception will be excluded
- Subjects who, in the investigator's judgement, pose a current significant suicidal or homicidal risk or patients who will not likely be able to comply with the study protocol
- Subjects fulfilling the DSM-IV diagnostic criteria for current substance abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Corn oil
|
The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids.
For the entire study period patients will receive 4 capsules of corn oil per day.
|
Experimental: Omega-3 fatty acids
|
The study drug is a food supplement called EPAX 6015 TG.
One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides.
For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
SDNN (msec)
Time Frame: at baseline and after 12 weeks
|
at baseline and after 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
LF/HF ratio
Time Frame: at baseline and after 12 weeks
|
at baseline and after 12 weeks
|
Time to new episode
Time Frame: study period (12 weeks)
|
study period (12 weeks)
|
Mood Rating Scales
Time Frame: at baseline and after 12 weeks
|
at baseline and after 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Emanuel Severus, M.D., Ludwig-Maximilians - University of Munich
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
April 28, 2009
First Submitted That Met QC Criteria
April 30, 2009
First Posted (Estimate)
May 1, 2009
Study Record Updates
Last Update Posted (Estimate)
April 12, 2013
Last Update Submitted That Met QC Criteria
April 11, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPAX 103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorders
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
National Human Genome Research Institute (NHGRI)CompletedBipolar Disorder (BD) | BipolarUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Mehmet Diyaddin GülekenCompletedBipolar I Disorder, Most Recent Episode Depressed
-
Elan PharmaceuticalsTerminatedBipolar Disorders
-
National Cheng-Kung University HospitalNational Science Council, TaiwanCompleted
-
University of California, San DiegoUniversity of Pennsylvania; Milken InstituteActive, not recruiting
Clinical Trials on Corn oil
-
University GhentJimma University; Nutricia Research Fundation; VLIR Institutional University... and other collaboratorsCompletedChild MalnutritionEthiopia
-
St. Luke's-Roosevelt Hospital CenterUSDA Beltsville Human Nutrition Research Center; Prosperity Organic FoodsCompletedChildhood ObesityUnited States
-
University of RochesterGlaxoSmithKline; Albany College of Pharmacy and Health SciencesTerminated
-
Laval UniversityCanadian Institutes of Health Research (CIHR)Completed
-
Universiti Sains MalaysiaCompleted
-
Columbia UniversityUnited States Department of Agriculture (USDA)CompletedObesity | Overweight | Pediatric ObesityUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
Gottfried Wilhelm Leibniz Universität HannoverCompleted
-
Vejle HospitalRecruitingColorectal Cancer | Peripheral NeuropathyDenmark